Prime Signed Value-Based Deal With EMD Serono for Mavenclad
Prime Therapeutics LLC recently unveiled that it had signed a value-based agreement for a relatively new multiple sclerosis (MS) drug with a complicated treatment regimen and high price tag.
In early June, the PBM said it had signed a deal with EMD Serono, Inc. for Mavenclad (cladribine) by which Prime would be financially compensated based on the rate at which members discontinue the therapy or switch to another MS drug over the typical course of treatment.
Related Posts

January 12
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
January 12
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE
January 12